Navigation Links
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/28/2009

- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo -

- First Active Cellular Immunotherapy for Cancer to Prolong Survival -

- Company to Host Webcast at 5:30 pm ET -

CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of significantly improving overall survival compared to placebo. The data were presented at the American Urological Association (AUA) Annual Meeting.

The intent-to-treat analysis demonstrated that:

  • PROVENGE extended median survival by 4.1 months compared to placebo (25.8 months versus 21.7 months);
  • PROVENGE improved 3-year survival by 38% compared to placebo (31.7% versus 23.0%);
  • The IMPACT study achieved a p-value of 0.032, successfully exceeding the pre-specified level of statistical significance defined by the study's design (p-value less than 0.043), and PROVENGE reduced the risk of death by 22.5% compared to placebo (HR=0.775); and
  • PROVENGE exhibited a favorable safety profile consistent with prior trials.

"These results confirm the clinical value of PROVENGE to prolong survival in patients with advanced prostate cancer. Moreover, it validates the longstanding but elusive aspiration to harness a patient's own immune system to fight cancer," said Philip Kantoff, MD, head of the prostate cancer program and chief of the division of solid tumor oncology at the Dana-Farber Cancer Institute and Harvard Medical School and a principal investigator of the IMPACT study.

PROVENGE is
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... in the upcoming Rodman & Renshaw 17 th ... in New York City .  Dr. ... a corporate overview on September 9, 2015. ...
(Date:9/4/2015)... -- Future Prospects for Companies in Antihistamines, ... drugs - new study showing you trends, partnerships, ... for allergic rhinitis drugs heading? What are the commercial ... shows you potential revenues and other trends to 2025, ... page report provides 273 tables, charts, and graphs. Discover ...
(Date:9/4/2015)... 2015 Research and ... of the "Pharmacovigilance (London, UK - December ... Understanding PhV today - the principles and ... Drug safety. This course aims to ... New entrants as well as experienced operators in ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
... life science tool company developing the third generation of ... over 5 years for the development of rapid, cost-effective ... grant, from the National Institute of Biomedical Imaging and ... will fund the project. QuantaLife is currently ...
... PCYC ) today reported financial results for its fiscal year ... During the fiscal year ended June 30, 2010, total revenue recognized ... fiscal year ended June 30, 2009.  The GAAP net loss reported ... or $0.31 per share. This compares to a GAAP net loss ...
Cached Medicine Technology:Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
(Date:9/3/2015)... ... September 03, 2015 , ... While bariatric surgeon Michael Feiz, M.D., F.A.C.S. ... preparing for a bariatric procedure, some patients have been recently asking further questions relating ... typical for many types of surgery that should be followed in the days prior ...
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... TransPack ... X. Users can choose from wipes and framing transitions in 30 different styles. ... made exclusively for Final Cut Pro X. , TransPack Toon features 90 cartoon transitions ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... William Mattar ... William Mattar, Esq. believes this does not stop at any certain demographic or segment ... its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning ...
(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve ... a leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting ... agreement, Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo School of ... chosen Center for Hospice Care (CHC) for physician Hospice and Palliative Medicine ... as part of fulfilling their requirements for obtaining national Board Certification in Hospice ...
Breaking Medicine News(10 mins):Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2
... In addition to the proposed ban on public smoking, which will ... the age limit of smokers from 16 to 18 years. ... start operating from October 2007. It would then be illegal to ... after 100 years of permitting sale of cigarettes to those over ...
... No Santa could have delivered a more welcome gift. ,Two-year-old Markus ... part of his father’s. , The operation was carried ... , A year ago Markus developed jaundice as a tumor ... orange. , He was put on an organ transplant list ...
... India working in hospitals in north Liverpool have recently been ... of their flats//, according to reports from Liverpool. ... nurses recruited by the National Health Service reside, have been ... to be getting worse. ,Minu Subash, a nurse ...
... Association (BMA) plans collaboration with the Indian Medical Association (IMA) ... medical graduates to train in Britain. ,BMA president Praveen ... national conference of the IMA, said: "I had a fruitful ... was eager for a close and active collaboration with the ...
... Stavis, 52, was able to eat the same pumpkin pie ... And when dinner was over, he didn’t have to reach ... transplant performed at Cedars-Sinai Medical Center in late October cured ... years. ,Oh, and a heart and kidney transplant ...
... caused irreparable damage to his kidneys and forced him to go ... Eliud was in Los Angeles, where he lives, and Jacqueline Lopez ... get the two together. ,Three Christmases ago, Eliud, who ... and 5, was healthy and active, working as a car detailer. ...
Cached Medicine News:Health News:Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again) 2Health News:Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again) 3Health News:Family and Friends Team Up to Provide LA Man With Kidney Transplant 2
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
Double ended with 0.5 mm x 10 mm and 0.5 mm x 15 mm blades. Both blades gently curved. Square serrated handle with polished finish. Most popular size or model....
11 mm angled tip with gently curved blade. Flat serrated handle with polished finish....
Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
Medicine Products: